Avecho Biotechnology Limited (AVEFF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.58 Million AUD | -96.45% |
| 2022 | -2.33 Million AUD | 31.42% |
| 2021 | -3.4 Million AUD | -29.58% |
| 2020 | -2.62 Million AUD | -371.09% |
| 2019 | 969.6 Thousand AUD | 118.76% |
| 2018 | -5.16 Million AUD | 47.33% |
| 2017 | -9.81 Million AUD | -103.45% |
| 2016 | -4.82 Million AUD | 23.18% |
| 2015 | -6.27 Million AUD | 51.35% |
| 2014 | -12.9 Million AUD | 28.95% |
| 2013 | -18.16 Million AUD | -13.75% |
| 2012 | -15.96 Million AUD | -20.46% |
| 2011 | -13.25 Million AUD | -437.36% |
| 2010 | 3.92 Million AUD | 143.38% |
| 2009 | -9.05 Million AUD | -109.68% |
| 2008 | 93.56 Million AUD | 888.82% |
| 2007 | -11.86 Million AUD | -35.52% |
| 2006 | -8.75 Million AUD | -126.33% |
| 2005 | -3.86 Million AUD | -119.9% |
| 2004 | -1.75 Million AUD | -129.06% |
| 2003 | -767.71 Thousand AUD | -229.49% |
| 2002 | -233 Thousand AUD | -113.7% |
| 2001 | 1.7 Million AUD | 177.28% |
| 2000 | -2.2 Million AUD | -318.54% |
| 1999 | 1 Million AUD | 113.04% |
| 1998 | -7.72 Million AUD | 83.25% |
| 1997 | -46.1 Million AUD | -585.24% |
| 1996 | -6.72 Million AUD | -117.54% |
| 1995 | 38.36 Million AUD | 3629.35% |
| 1994 | -1.08 Million AUD | -146.69% |
| 1993 | 2.32 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.44 Million AUD | 0.0% |
| 2024 Q1 | -1.44 Million AUD | 29.95% |
| 2023 Q2 | -2.52 Million AUD | -138.01% |
| 2023 Q3 | -650.63 Thousand AUD | 74.21% |
| 2023 Q4 | -2.06 Million AUD | -217.6% |
| 2023 Q1 | -1.05 Million AUD | 46.56% |
| 2023 FY | -4.58 Million AUD | -96.45% |
| 2022 FY | -2.33 Million AUD | 31.42% |
| 2022 Q3 | -781.01 Thousand AUD | 27.71% |
| 2022 Q1 | -387 Thousand AUD | 83.67% |
| 2022 Q2 | -1.08 Million AUD | -179.16% |
| 2022 Q4 | -1.98 Million AUD | -153.97% |
| 2021 Q2 | -2.18 Million AUD | -151.86% |
| 2021 Q1 | -865.95 Thousand AUD | 54.76% |
| 2021 Q4 | -2.36 Million AUD | -183.08% |
| 2021 FY | -3.4 Million AUD | -29.58% |
| 2021 Q3 | -837.12 Thousand AUD | 61.62% |
| 2020 Q4 | -1.91 Million AUD | -188.19% |
| 2020 FY | -2.62 Million AUD | -371.09% |
| 2020 Q2 | -1.47 Million AUD | -98.45% |
| 2020 Q1 | -742.47 Thousand AUD | 49.41% |
| 2020 Q3 | -664.14 Thousand AUD | 54.93% |
| 2019 Q3 | -760.97 Thousand AUD | -137.03% |
| 2019 Q4 | -1.46 Million AUD | -92.87% |
| 2019 Q2 | 2.05 Million AUD | 101.78% |
| 2019 FY | 969.6 Thousand AUD | 118.76% |
| 2019 Q1 | 1.01 Million AUD | 186.68% |
| 2018 Q2 | -1.31 Million AUD | 0.0% |
| 2018 Q4 | -1.17 Million AUD | 0.0% |
| 2018 Q3 | -1.17 Million AUD | 10.52% |
| 2018 FY | -5.16 Million AUD | 47.33% |
| 2018 Q1 | -1.31 Million AUD | 0.0% |
| 2017 Q2 | -2.37 Million AUD | 0.0% |
| 2017 Q1 | -2.37 Million AUD | 14.85% |
| 2017 FY | -9.81 Million AUD | -103.45% |
| 2016 Q1 | -3.22 Million AUD | 12.48% |
| 2016 Q3 | -2.79 Million AUD | 13.42% |
| 2016 Q2 | -3.22 Million AUD | 0.0% |
| 2016 Q4 | -2.79 Million AUD | 0.0% |
| 2016 FY | -4.82 Million AUD | 23.18% |
| 2015 Q4 | -3.68 Million AUD | 0.0% |
| 2015 FY | -6.27 Million AUD | 51.35% |
| 2015 Q1 | -3.37 Million AUD | 4.33% |
| 2015 Q2 | -3.37 Million AUD | 0.0% |
| 2015 Q3 | -3.68 Million AUD | -9.2% |
| 2014 Q1 | -2.75 Million AUD | -10.06% |
| 2014 FY | -12.9 Million AUD | 28.95% |
| 2014 Q4 | -3.52 Million AUD | 0.0% |
| 2014 Q3 | -3.52 Million AUD | -27.85% |
| 2014 Q2 | -2.75 Million AUD | 0.0% |
| 2013 Q3 | -4.5 Million AUD | -8.2% |
| 2013 FY | -18.16 Million AUD | -13.75% |
| 2013 Q4 | -2.5 Million AUD | 44.41% |
| 2013 Q2 | -4.16 Million AUD | 0.0% |
| 2013 Q1 | -4.16 Million AUD | 0.0% |
| 2012 FY | -15.96 Million AUD | -20.46% |
| 2011 FY | -13.25 Million AUD | -437.36% |
| 2010 FY | 3.92 Million AUD | 143.38% |
| 2009 FY | -9.05 Million AUD | -109.68% |
| 2008 FY | 93.56 Million AUD | 888.82% |
| 2007 FY | -11.86 Million AUD | -35.52% |
| 2006 FY | -8.75 Million AUD | -126.33% |
| 2005 FY | -3.86 Million AUD | -119.9% |
| 2004 FY | -1.75 Million AUD | -129.06% |
| 2003 FY | -767.71 Thousand AUD | -229.49% |
| 2002 FY | -233 Thousand AUD | -113.7% |
| 2001 FY | 1.7 Million AUD | 177.28% |
| 2000 FY | -2.2 Million AUD | -318.54% |
| 1999 FY | 1 Million AUD | 113.04% |
| 1998 FY | -7.72 Million AUD | 83.25% |
| 1997 FY | -46.1 Million AUD | -585.24% |
| 1996 FY | -6.72 Million AUD | -117.54% |
| 1995 FY | 38.36 Million AUD | 3629.35% |
| 1994 FY | -1.08 Million AUD | -146.69% |
| 1993 FY | 2.32 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -227.334% |
| CSL Limited | 3.7 Billion USD | 100.124% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 93.607% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 193.375% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1653.433% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 74.286% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 105.607% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -198.766% |
| Mesoblast Limited | -84.14 Million USD | 94.546% |
| Marizyme, Inc. | -34.08 Million USD | 86.537% |
| Genus plc | 6.4 Million USD | 171.706% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 147.105% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -392.73% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 45.04% |
| ContraFect Corporation | -56.88 Million USD | 91.933% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -0.757% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -38.67 Million USD | 88.133% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -66.829% |
| MultiCell Technologies, Inc. | -722.81 USD | -634809.451% |
| Accustem Sciences Inc. | -3.74 Million USD | -22.495% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 92.22% |
| EV Biologics, Inc. | -483.06 Thousand USD | -850.021% |
| Q BioMed Inc. | -3.44 Million USD | -33.189% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 229.638% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -74.658% |
| Biomind Labs Inc. | -1 Million USD | -354.554% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 30.969% |
| Skye Bioscience, Inc. | -13.67 Million USD | 66.433% |
| SQZ Biotechnologies Company | -75.82 Million USD | 93.948% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -15221.812% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 9.026% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -60.996% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 71.082% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1078.014% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 5.95% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -131.021% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -137.461% |
| GB Sciences, Inc. | -1.42 Million USD | -223.067% |
| Alpha Cognition Inc. | -9.7 Million USD | 52.716% |
| argenx SE | -425.04 Million USD | 98.92% |
| HST Global, Inc. | -140.9 Thousand USD | -3156.892% |
| Halberd Corporation | -75.05 Thousand USD | -6014.842% |
| Enzolytics Inc. | -2.14 Million USD | -113.57% |
| Resverlogix Corp. | -12.74 Million USD | 64.004% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -44.848% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 91.732% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 91.652% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -339.577% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -58.18% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -57.194% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -146.152% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -190.574% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -34.779% |
| AVAX Technologies, Inc. | 6.69 Million USD | 168.568% |
| ONE Bio Corp. | 13.68 Million USD | 133.543% |
| Zenith Capital Corp. | -8.94 Million USD | 48.684% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.896% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -26242.856% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -86.908% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2575.763% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -128.915% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -307.962% |
| Agentix Corp. | -1.37 Million USD | -234.548% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.04 Million USD | -50.948% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -366.356% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -265.381% |
| BioStem Technologies, Inc. | -7.77 Million USD | 41.005% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2428.688% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -243.649% |
| LadRx Corporation | -3.82 Million USD | -20.022% |
| Cell Source, Inc. | -4.32 Million USD | -6.1% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1004.554% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -568.053% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -568.053% |
| NovAccess Global Inc. | -2.46 Million USD | -86.041% |
| Affymax, Inc. | -15.04 Million USD | 69.499% |
| Itoco Inc. | -919.14 Thousand USD | -399.292% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -8.276% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -310.115% |
| CytoDyn Inc. | -18.05 Million USD | 74.586% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -18132.773% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1985.256% |
| Qrons Inc. | -643.67 Thousand USD | -612.965% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -712.644% |
| SYBLEU INC | -149.18 Thousand USD | -2976.276% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -105.804% |
| Rebus Holdings, Inc. | -664 Thousand USD | -591.143% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -152.664% |
| Mobile Lads Corp. | -554.55 Thousand USD | -727.552% |
| International Stem Cell Corporation | -663 Thousand USD | -592.185% |
| Bioxytran, Inc. | -3.82 Million USD | -20.131% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8618.064% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -22462.384% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 87.346% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -183.633% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -523.671% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -47.515% |
| Neutra Corp. | -229.48 Thousand USD | -1899.769% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 73.834% |
| PureTech Health plc | -146.19 Million USD | 96.861% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 78.646% |
| IXICO plc | -1.43 Million USD | -219.359% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 51.647% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.232% |
| CSL Limited | 3.81 Billion USD | 100.12% |
| Cellectis S.A. | -108.85 Million USD | 95.784% |